High-risk #ProstateCancer patients may benefit from precision-tailored neoadjuvant therapy. Dr. Martin E. Gleave, CM, MD, FRCSC, FACS, Director, Vancouver Prostate Centre, explains the GUNS trial, now enrolling 280+ patients.

New research in Nature Communications from investigators at the Vancouver Prostate Centre shows plasma ctDNA testing is a valuable adjunct to tissue testing for detecting FGFR alterations in metastatic urothelial cancer and may identify additional patients eligible for therapy.

Congratulations to Dr. Ewan Gibb, from the Vancouver Prostate Centre, on his latest publication in European Urology Oncology! Dr. Ewan Gibb introduces a long non-coding RNA classifier that helps identify hidden biological risk in early low-grade bladder cancer.

“This classifier could help clinicians see which tumors may recur despite appearing low-risk,” says Dr. Gibb. This work advances personalized bladder cancer care and adds critical insight for intermediate-risk patients.

New paper from Dr. Alex Wyatt and his team: increased clonal hematopoiesis observed following radioligand therapy in mCRPC. Led by PhD student Asli Munzur and in collaboration with ANZUP trial group in Australia. 🌐 Read here: doi.org/10.1158/1078-0432.CC…

Vancouver Prostate Centre is pleased to announce $1.01M in CIHR funding awarded to Dr. Alex Wyatt to advance circulating tumor DNA (ctDNA) biomarkers for treatment response in metastatic prostate cancer. 🔗Read more on VPC News! prostatecentre.com/news/dr-a…

New research from the Vancouver Prostate Centre, led by Dr. Dong Gao, published in JCI Insight, shows how UGT2B17 drives resistance to androgen deprivation therapy through non-canonical mechanisms. PMID: 41343245 pubmed.ncbi.nlm.nih.gov/4134…

Researchers at the Vancouver Prostate Centre, led by Prof. Wilfred A. Jefferies, have developed Gemini, a self-amplifying vaccine and nanomedicine platform designed to overcome key limitations of current mRNA technologies. 🔗 nature.com/articles/s41467-0…